You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
雲頂新耀-B(01952.HK)與AbCellera開展多靶點合作推進新抗體藥物研發
格隆匯 09-23 06:13

格隆匯9月23日丨雲頂新耀-B(01952.HK)發佈公吿,AbCellera Biologics Inc.與公司達成一項多年度研發合作協議,針對公司選擇的多達10種靶點開展研究,發現治療性抗體。該合作伙伴關係將有助於擴大公司在多個適應症領域的新藥組合,初始項目將專注於腫瘤相關靶點。

通過與AbCellera合作,公司將受益於其支持多種抗體發現模式的運營體系,以拓展新的靶點種類以及開闢新的疾病治療領域和療法。此次合作將充分利用AbCellera整體技術能力,包括從Trianni Mouse®獲得完全人源化的抗體,從camelids獲取單抗,以及使用OrthoMabTM蛋白工程平台將任意兩種抗體合成天然雙抗。

根據協議條款,公司將有權開發和商業化基於合作研發的抗體。AbCellera將獲得研究費用,並有資格獲得公司在下游臨牀研究、商業里程碑付款,以及基於產品淨銷售額的特許權使用費。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account